The role of IFN-γ in rejection of established tumors by IL-12: Source of production and target

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4696-4703

  Segal, Jennifer Gillary ^a   Lee, Natalie C ^a   Tsung, Ying L ^a   Norton, Jeffrey A ^a   Tsung, Kangla ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TYPE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST CELL; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TH1 CELL; TUMOR REJECTION;

ANIMALS; CARCINOGENS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 0037102374     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Liver NK1.1+ CD4+ α β T cells activated by IL- 12 as a major effector in inhibition of experimental tumor metastasis
2. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
3. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells
4. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo
5. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor
6. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites
7. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity
8. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12
9. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus-unresponsive tumor models
10. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
11. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells
12. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12
13. Immune response against large tumors eradicated by treatment with cyclophosphamide and interleukin-12
14. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12
15. IL-12 induces T helper 1-directed antitumor response
16. Immune rejection of a large sarcoma following cyclophosphamide and il-12 treatment requires both nk and nk t cells and is associated with the induction of a novel nk t cell population
17. Induction of interferon γγγproduction by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers
18. Administration of recombinant IL-12 to normal mice enhances cytolylic lymphocyte activity and induces production of IFN-γ in vivo
19. IFN-γ production by antigen-presenting cells: Mechanisms emerge
20. The structure and function of interferon-γ receptors
21. IL-12-induced tumor regression correlates with in situ activity of IFN-γ produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways
22. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12
23. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors
24. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
25. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
26. Multiple roles of interferon-γ in the mediation of interleukin 12-induced tumor regression
27. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice
28. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
29. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
30. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice
31. Multiple defects of immune cell function in mice with disrupted interferon-γ genes
32. Immunotherapy of melanoma: A dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy
33. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice
34. Recombinant mouse γ interferon induces the priming step in macrophage activation for tumor cell killing
35. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1 +, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells
36. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762
37. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells
38. The central role of CD4(+) T cells in the antitumor immune response
39. Antigen-specific activation of effector macrophages by IFN-γ producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages
40. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection
41. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection
42. A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability